California Public Employees Retirement System Has $258.93 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

California Public Employees Retirement System decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 363,496 shares of the biopharmaceutical company’s stock after selling 8,142 shares during the period. California Public Employees Retirement System’s holdings in Regeneron Pharmaceuticals were worth $258,929,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $28,000. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares in the last quarter. Avalon Trust Co acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $36,000. Finally, Crowley Wealth Management Inc. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $36,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on REGN shares. Citigroup reduced their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Bernstein Bank dropped their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research note on Tuesday, February 4th. Finally, Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Up 0.2 %

NASDAQ REGN opened at $637.36 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $629.02 and a twelve month high of $1,211.20. The stock has a market cap of $69.68 billion, a PE ratio of 16.65, a PEG ratio of 2.34 and a beta of 0.27. The firm has a 50-day simple moving average of $683.88 and a 200 day simple moving average of $797.99. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $11.86 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.